| Description | This product is a human antibody may be a promising component of preventive or therapeutic intervention. Furthermore, the unique epitopes revealed by mab suggest priorities for rational vaccine design based on novel immunogens with cross-reactive neutralizing determinants. This antibody showed the greatest cross-neutralizing potency, neutralizing DENV1, DENV2, and DENV3 at or below 0.06 µg/mL. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | Dengue Virus (DENV) |
| Cross Reactivity | DENV1, DENV2, DENV3 |
| Epitope | The critical residues of epitope includes residues 73, 78, and 79 in the bc loop of E protein. |
| EC50 | 0.06 µg/mL |
| Isotype | Human IgG |
| Expression Species | HEK293F or CHO |
| Conjugation | None |
| Purity | >95%, determined by SDS-PAGE and SEC-HPLC |
| Endotoxin | <1 EU/mg |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within a week. For longer storage, aliquot and store at -20°C. |
| Application | ELISA; Neut; FC; FRNT |
| Application Notes | The antibody 1C19 is recommended for detection of DENV E protein by ELISA and Neutralization. 1C19 exhibited its high potency in cross-neutralization, effectively neutralizing DENV1, DENV2, and DENV3 at or below a concentration of 0.06 µg/ml. MAb 1C19 reduced DENV2 replication at a relatively low dose of 20 µg per mouse. The neutralizing potency of MAbs was measured using a flow cytometry-based neutralization assay with Vero cells. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | DENV E protein |
| Alternative Name | Dengue virus envelope protein; Dengue virus; envelope protein; DENV1; EP; DENV; DENV1; DENV2; DENV3 |
| Research Area | Infectious Disease |
